Combining CD4 count, CD8 count and CD4/CD8 ratio to predict risk of mortality among HIV-positive adults after therapy: a group-based multi-trajectory analysis

被引:1
|
作者
Ma, Jing [1 ,2 ]
Wang, Guoyong [2 ,3 ]
Zhu, Xiaoyan [2 ,3 ]
Li, Ling [2 ,3 ]
Wang, Lin [2 ,3 ]
Hao, Lianzheng [2 ,3 ]
Gao, Lijie [1 ,2 ]
Ma, Wei [1 ,2 ]
Zhang, Na [2 ,3 ]
机构
[1] Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Dept Epidemiol, Jinan, Shandong, Peoples R China
[2] Shandong Univ, Inst Prevent Med, Jinan, Shandong, Peoples R China
[3] Shandong Ctr Dis Control & Prevent, Inst Acquired Immunodeficiency Syndrome AIDS Contr, Jinan, Shandong, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
CD4; count; CD8; CD4/CD8; ratio; HIV; antiretroviral therapy; mortality; ACTIVE ANTIRETROVIRAL THERAPY; DISEASE PROGRESSION; CELL RECOVERY; COHORT; INDIVIDUALS; SUPPRESSION; PERCENTAGE; INITIATION; INFECTION;
D O I
10.3389/fimmu.2023.1269650
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IntroductionPrevious studies have indicated different immunological recovery trajectories based on CD4 count or CD4/CD8 ratio. However, these immune indicators are interconnected, and relying solely on one indicator may lead to inaccurate estimates. Therefore, it is essential to develop a comprehensive trajectory model that integrates CD4 count, CD8 count and CD4/CD8 ratio.MethodsWe utilized a group-based multi-trajectory model to characterize the latent cluster of recovery based on measurements of CD4 count, CD8 count and CD4/CD8 ratio over a period of up to 96 months following ART initiation. Subsequently, we investigated the characteristics associated with trajectory groups, especially sex and age. Cox model and Kaplan-Meier survival curve were employed to assess differences in all-cause, AIDS-related and non-AIDS related mortality between trajectory groups.ResultsA total of 14,718 eligible individuals were followed for a median of 55 months. Longitudinal model identified four subgroups: group 1 (32.5%, low CD4 and CD4/CD8 inversion), group 2 (25.9%, high CD8 and CD4/CD8 inversion), group 3 (27.2%, slow recovery of CD4 and CD4/CD8 inversion) and group 4 (14.4%, rapid increase of CD4 and normal CD4/CD8). Immune recovery was slower in male than in female, and in elders than in youngers. Compared to group 2, group 1 (adjusted hazard ratio [aHR]=3.28; 95% CI 2.33-4.60) and group 3 (aHR=1.56; 95% CI 1.09-2.24) had increased risk of all-cause mortality after adjusting for other factors. Besides, group 1 (aHR=2.17) and group 3 (aHR=1.58) had higher risk of non-AIDS related mortality, and group 1 (aHR=5.92) had significantly increased risk of AIDS related mortality.ConclusionLongitudinal trajectory analysis of multiple immune indicators can be employed to guide targeted interventions among vulnerable populations in clinical practice.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] CD4/CD8 Ratio Predicts Peripheral Fat in HIV-Infected Population
    Riangwiwat, Tanawan
    Kohorn, Lindsay B.
    Chow, Dominic C.
    Souza, Scott A.
    Ndhlovu, Lishomwa C.
    Wong, Jennifer W. H.
    Gangcuangco, Louie Mar
    Shikuma, Cecilia M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (01) : E17 - E19
  • [42] THE EFFECT OF PROPOLIS SUPPLEMENTATION TO CD4/CD8 RATIO IN HIV-INFECTED PATIENTS RECEIVING ANTIRETROVIRAL REGIMEN THERAPY
    Triyono, E. A.
    Firdausa, S.
    Prasetyo, H.
    Susanto, J.
    Hutagalung, J.
    Masyfufah, L.
    Hadi, U.
    NEW ARMENIAN MEDICAL JOURNAL, 2019, 13 (04): : 85 - 94
  • [43] CMV plus Serostatus Associates Negatively with CD4:CD8 Ratio Normalization in Controlled HIV-Infected Patients on cART
    Poizot-Martin, Isabelle
    Allavena, Clotilde
    Duvivier, Claudine
    Cano, Carla Eliana
    de Salvador, Francine Guillouet
    Rey, David
    Dellamonica, Pierre
    Cuzin, Lise
    Cheret, Antoine
    Hoen, Bruno
    PLOS ONE, 2016, 11 (11):
  • [44] CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients
    Lu, Wei
    Mehraj, Vikram
    Vyboh, Kishanda
    Cao, Wei
    Li, Taisheng
    Routy, Jean-Pierre
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18
  • [45] Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events
    Serrano-Villar, Sergio
    Wu, Kunling
    Hunt, Peter W.
    Lok, Judith J.
    Ron, Raquel
    Sainz, Talia
    Moreno, Santiago
    Deeks, Steven G.
    Bosch, Ronald J.
    EBIOMEDICINE, 2022, 80
  • [46] CD4/CD8 Cell Ratio in Acute HIV Infection and the Impact of Early Antiretroviral Therapy
    Hoenigl, Martin
    Chaillon, Antoine
    Little, Susan J.
    CLINICAL INFECTIOUS DISEASES, 2016, 63 (03) : 425 - +
  • [47] The predictive role of CD4+ cell count and CD4/CD8 ratio in immune reconstitution outcome among HIV/AIDS patients receiving antiretroviral therapy: an eight-year observation in China
    Li, Chong-Xi
    Li, Yu-Ye
    He, Li-Ping
    Kou, Jing
    Bai, Jin-Song
    Liu, Jun
    Tian, Bo
    Cao, Li-Juan
    Wang, Kun-Hua
    Kuang, Yi-Qun
    BMC IMMUNOLOGY, 2019, 20 (01)
  • [48] Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy
    Winston, Alan
    Jose, Sophie
    Fisher, Martin
    Walsh, John
    Nelson, Mark
    Gilson, Richard
    Post, Frank
    Johnson, Margaret
    Leen, Clifford
    Chadwick, David
    Hay, Phillip
    Pritchard, Jillian
    Tariq, Anjum
    Sabin, Caroline
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 136 (06) : 1682 - 1685
  • [49] CD4/CD8 ratio improvement in HIV-1-infected patients receiving dual antiretroviral treatment
    Monsalvo, Marta
    Vallejo, Alejandro
    Fontecha, Maria
    Vivancos, Maria J.
    Vizcarra, Pilar
    Casado, Jose L.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2019, 30 (07) : 656 - 662
  • [50] CD4/CD8 Ratio During Human Immunodeficiency Virus (HIV) Treatment: Time for Routine Monitoring?
    Ron, Raquel
    Moreno, Elena
    Martinez-Sanz, Javier
    Branas, Fatima
    Sainz, Talia
    Moreno, Santiago
    Serrano-Villar, Sergio
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (09) : 1688 - 1696